Journal
CANCER RESEARCH
Volume 70, Issue 4, Pages 1281-1285Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-09-3276
Keywords
-
Categories
Funding
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- Institut Gustave Roussy
- Institut Curie
- l'Institut National du Cancer
- la Fondation Bettencourt Schueller
- Fondation de France
Ask authors/readers for more resources
Exosomes are nanovesicles originating from late endosomal compartments and secreted by most living cells in ex vivo cell culture conditions. The interest in exosomes was rekindled when B-cell and dendritic cell-derived exosomes were shown to mediate MHC-dependent immune responses. Despite limited understanding of exosome biogenesis and physiological relevance, accumulating evidence points to their bioactivity culminating in clinical applications in cancer. This review focuses on the preclinical studies exploiting the immunogenicity of dendritic cell-derived exosomes (Dex) and will elaborate on the past and future vaccination trials conducted using Dex strategy in melanoma and non-small cell lung cancer patients. Cancer Res; 70(4); 1281-5. (C) 2010 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available